Executive Editor, MTI; Medtech Editor, In Vivo
Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest From Ashley Yeo
Are too few digital health care apps approved for reimbursement in Germany? That’s not the point, says the health care ministry, urging a look at the bigger strategic picture.
Another key stage has been reached in Switzerland’s bid to enable US FDA-approved medtech to be used in the local population.
Digitization of the German health care system has been slow to get going, as the health ministry readily admits. A fresh start should bring different results, the ministry’s head of e-health Sebastian Zilch told Medica attendees.
The UK government’s new procurement-and-beyond body housed in the DHSC says a medtech strategy could hit the presses before 2023. The medtech industry is cheered by promises of engagement.
Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators.
A typical word cloud for discussions around patient-centered care would feature: business model, digital health, financing, PPP, resources, data sharing, staffing and escalation of costs. But so many other words are missing, which is why patient-centricity risks getting stuck in its current incomplete form. What are medtechs to do?